Format

Send to

Choose Destination
See comment in PubMed Commons below
Curr Opin Hematol. 2010 Jul;17(4):276-80. doi: 10.1097/MOH.0b013e328339f2ee.

Evolution of induced pluripotent stem cell technology.

Author information

1
Department of Chemistry, The Scripps Research Institute, La Jolla, California 92037, USA.

Abstract

PURPOSE OF REVIEW:

Induced pluripotent stem cell (iPSC) technology, which uses defined transcription factors to reprogram somatic cells to become pluripotent cells, offers a significant technical simplicity and enables generation of patient-specific pluripotent stem cells with reduced ethical concerns. This review will focus on recent progresses in understanding of iPSCs and improved methods of generating iPSCs.

RECENT FINDINGS:

Whereas iPSCs generated from a variety of cell sources were found to be nearly identical functionally to embryonic stem cells, some differences were also identified and remain to be characterized. Meanwhile, new methods of generating iPSCs with minimal or no exogenous genetic modifications to cells have advanced rapidly.

SUMMARY:

iPSC technology provides unprecedented opportunities in biomedical research and regenerative medicine. However, there remain a great deal to learn about iPSC safety, the reprogramming mechanisms, and better ways to direct a specific reprogramming process. The iPSC field will flourish on its mechanistic studies, iPSC-based disease modeling, and identification of new small molecules that modulate reprogramming.

PMID:
20442654
DOI:
10.1097/MOH.0b013e328339f2ee
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Lippincott Williams & Wilkins
    Loading ...
    Support Center